Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Paradigm shift in NMDA receptor drug development.

Stuart A Lipton, H-S Vincent Chen

    Expert Opinion on Therapeutic Targets
    |June 14, 2005
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Molecular and Structural Characterization Reveals Divergent Extracellular Vesicle Profiles Between Wild Type and Alzheimer's Disease Cerebrocortical Organoids.

    bioRxiv : the preprint server for biology·2026
    Same author

    Redox regulation of neuroinflammatory pathways contributes to damage in Alzheimer's disease brain.

    Cell chemical biology·2026
    Same author

    Aberrant Protein S-Nitrosylation Mimics the Effect of Rare Genetic Mutations in Neurodegenerative Diseases.

    Journal of neurochemistry·2026
    Same author

    Autophagy Activators Normalize Aberrant Tau Proteostasis and Rescue Synapses in Human Familial Alzheimer's Disease iPSC-Derived Cortical Organoids.

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
    Same author

    Basic Science and Pathogenesis.

    Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
    Same author

    The transcriptional and cellular landscape of cognitive resilience to Alzheimer's disease.

    Frontiers in molecular neuroscience·2025

    Low-affinity, uncompetitive antagonists like memantine protect against neurological disorders. These drugs challenge traditional high-affinity binding screening methods for new drug discovery.

    Area of Science:

    • Neuroscience
    • Pharmacology
    • Drug Discovery

    Background:

    • Neurological disorders, including dementia, represent a significant unmet medical need.
    • Current drug discovery paradigms often prioritize high-affinity binding interactions.
    • Memantine, a low-affinity, uncompetitive antagonist, demonstrates therapeutic efficacy in neurological conditions.

    Discussion:

    • The efficacy of low-affinity antagonists like memantine suggests a need to re-evaluate traditional drug screening criteria.
    • Rapid dissociation rates ('off-rates') may be crucial for the therapeutic action of certain neurological drugs.
    • Understanding the mechanisms of low-affinity drugs can inform the development of novel therapeutic strategies.

    Key Insights:

    • Low-affinity, uncompetitive antagonists can provide neuroprotection.

    Related Experiment Videos

  • Drug screening models may need to incorporate parameters beyond high-affinity binding.
  • Memantine serves as a key example of successful low-affinity antagonist therapy.

    • Outlook:

    • Future drug discovery for neurological disorders should consider a broader range of binding affinities and kinetics.
    • Further research into the 'off-rate' phenomenon could unlock new therapeutic targets.
    • Developing new screening assays that account for low-affinity interactions is essential for advancing neurological drug development.